Allogeneic Stem Cell Therapy Falls Short on Stroke Outcomes
(MedPage Today) -- Bone marrow-derived allogeneic stem cell therapy shortly after ischemic stroke did not improve outcomes at 90 days, a phase II/III randomized clinical trial known as TREASURE found.
The rate of excellent outcomes -- a composite...
Source: MedPage Today Cardiovascular - Category: Cardiology Source Type: news
More News: Cardiology | Cardiovascular | Clinical Trials | Heart | Ischemic Stroke | Stem Cell Therapy | Stem Cells | Stroke